Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | Siglec-10 |
| Synonyms | Sialic acid-binding Ig-like lectin 10; SLG2; SIGLEC10 |
| Location | Cell membrane |
| Accession | Q96LC7 |
| Clone Number | S-4483 |
| Antibody Type | Mouse mAb |
| Isotype | IgG1,k |
| Application | FCM |
| Reactivity | Hu |
| Purification | Protein G |
| Concentration | 2 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1:200 | Hu |
Background
Siglec-10 (Sialic acid-binding Ig-like lectin 10) is an inhibitory immune checkpoint receptor primarily expressed on the surface of human myeloid cells, including monocytes, macrophages, and dendritic cells, which plays a critical role in maintaining immune tolerance and preventing excessive inflammation. Structurally characterized by an N-terminal V-set Ig-like domain that specifically recognizes sialic acid residues on glycan chains, Siglec-10 transmits negative regulatory signals upon ligand binding through its cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and ITIM-like sequences, thereby recruiting phosphatases such as SHP-1 and SHP-2 to dampen downstream activating signaling pathways. This receptor is notably involved in distinguishing self from non-self by interacting with "self-associated molecular patterns" (SAMPs), a mechanism that suppresses immune responses against healthy host tissues but can be co-opted by tumors to evade immune surveillance; consequently, blocking the interaction between Siglec-10 and its sialylated ligands has emerged as a promising therapeutic strategy in cancer immunotherapy to reactivate anti-tumor immunity, while its dysfunction is also implicated in various inflammatory disorders and infectious diseases where pathogen mimicry of host glycans exploits this inhibitory pathway.
